Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus

J Cinatl, B Morgenstern, G Bauer, P Chandra, H Rabenau, H W Doerr, J Cinatl, B Morgenstern, G Bauer, P Chandra, H Rabenau, H W Doerr

Abstract

The outbreak of SARS warrants the search for antiviral compounds to treat the disease. At present, no specific treatment has been identified for SARS-associated coronavirus infection. We assessed the antiviral potential of ribavirin, 6-azauridine, pyrazofurin, mycophenolic acid, and glycyrrhizin against two clinical isolates of coronavirus (FFM-1 and FFM-2) from patients with SARS admitted to the clinical centre of Frankfurt University, Germany. Of all the compounds, glycyrrhizin was the most active in inhibiting replication of the SARS-associated virus. Our findings suggest that glycyrrhizin should be assessed for treatment of SARS.

Figures

Figure
Figure
Effect of glycyrrhizin on replication of SARS-associated coronavirus in Vero cells Cells were fixed with 60 parts methanol to 40 parts acetone 72 h after infection. Virus was detected in serum from the patient with SARS by peroxidase staining. (A) mock infected cells. (B) infected cells without treatment. (C) infected cells treated with 4000 mg/L glycyrrhizin. (D) infected cells treated with 1000 mg/L glycyrrhizin.

References

    1. Drosten C, Gunther S, Preiser W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–1976.
    1. Crance JM, Scaramozzino N, Jouan A, Garin D. Interferon, ribavirin, 6-azauridine, and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res. 2003;58:73–79.
    1. Jeong HG, Kim JY. Induction of inducible nitric oxide synthase expression by 18β-glycyrrhetinic acid in macrophages. FEBS Lett. 2002;513:208–212.
    1. Lin YL, Huang YL, Ma SH. Inhibition of Japanese encephalitis virus infection by nitric oxide: antiviral effect of nitric oxide on RNA virus replication. J Virol. 1997;71:5227–5235.
    1. Booth CM, Matukas LM, Tomlinson GA. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:1–9.

Source: PubMed

3
Se inscrever